238 related articles for article (PubMed ID: 12817772)
1. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective.
Rosenblatt M
J Bone Miner Res; 2003 Jun; 18(6):1142-5. PubMed ID: 12817772
[TBL] [Abstract][Full Text] [Related]
2. Study design in osteoporosis: a European perspective.
Kanis JA; Alexandre JM; Bone HG; Abadie E; Brasseur D; Chassany O; Durrleman S; Lekkerkerker JF; Caulin F
J Bone Miner Res; 2003 Jun; 18(6):1133-8. PubMed ID: 12817770
[TBL] [Abstract][Full Text] [Related]
3. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?
Brody BA; Dickey N; Ellenberg SS; Heaney RP; Levine RJ; O'Brien RL; Purtilo RB; Weijer C
J Bone Miner Res; 2003 Jun; 18(6):1105-9. PubMed ID: 12817764
[TBL] [Abstract][Full Text] [Related]
4. Is it ethical to use placebos in osteoporosis trials?
Ragi-Eis S; Zerbini CA; Provenza JR; Griz LH; de Gregório LH; Russo LA; Silva NA; Borges JL; de Souza AC; Castro ML; Lewiecki EM
J Clin Densitom; 2006; 9(3):274-80. PubMed ID: 16931344
[TBL] [Abstract][Full Text] [Related]
5. Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis.
Pak CY; Adams-Huet B; Sakhaee K; Bell NH; Licata A; Johnston C; Rubin B; Bonnick S; Piziak V; Graham H; Ballard J; Berger R; Fears W; Breslau N; Rubin C
J Bone Miner Res; 1996 Feb; 11(2):160-8. PubMed ID: 8822339
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF).
Silverman SL; Cummings SR; Watts NB;
J Bone Miner Res; 2008 Jan; 23(1):159-65. PubMed ID: 17892379
[TBL] [Abstract][Full Text] [Related]
7. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
8. The ethics of placebo-controlled trials: the case of asthma.
Onder RF
J Allergy Clin Immunol; 2005 Jun; 115(6):1228-34. PubMed ID: 15940139
[TBL] [Abstract][Full Text] [Related]
9. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
10. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
12. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study.
McCloskey EV; Beneton M; Charlesworth D; Kayan K; deTakats D; Dey A; Orgee J; Ashford R; Forster M; Cliffe J; Kersh L; Brazier J; Nichol J; Aropuu S; Jalava T; Kanis JA
J Bone Miner Res; 2007 Jan; 22(1):135-41. PubMed ID: 17042717
[TBL] [Abstract][Full Text] [Related]
13. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
14. [Hormone replacement therapy and its derivatives in the prevention and treatment of osteoporosis].
Lamy O; Krieg MA
Rev Med Suisse Romande; 2002 Aug; 122(8):377-81. PubMed ID: 12357730
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
16. Placebo controls in clinical trials of new therapies for osteoporosis.
Levine RJ
J Bone Miner Res; 2003 Jun; 18(6):1154-9. PubMed ID: 12817775
[No Abstract] [Full Text] [Related]
17. Current and investigational approaches for reversing established osteoporosis.
Kimmel DB; Slovik DM; Lane NE
Rheum Dis Clin North Am; 1994 Aug; 20(3):735-58. PubMed ID: 7984787
[TBL] [Abstract][Full Text] [Related]
18. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study.
Katz KA; Karlawish JH; Chiang DS; Bognet RA; Propert KJ; Margolis DJ
J Am Acad Dermatol; 2006 Nov; 55(5):814-22. PubMed ID: 17052487
[TBL] [Abstract][Full Text] [Related]
20. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
